Drug Profile
MDL 63166
Latest Information Update: 30 Sep 2005
Price :
$50
*
At a glance
- Originator Biosearch Italia
- Class Amino acids; Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
- 14 Jul 1998 No-Development-Reported for Bacterial infections in Italy (Unknown route)
- 17 Oct 1995 Preclinical development for Bacterial infections in Italy (Unknown route)